news
Epigenetic aging clocks need better trials, says Nature Medicine
A new piece in Nature Medicine argues that current epigenetic aging clocks, which measure biological age, lack robust clinical trials. The article calls for larger, randomized studies to validate these tools before they see wider adoption for health interventions. It’s a call to action for the longevity industry.
A new piece in Nature Medicine argues that current epigenetic aging clocks, which measure biological age, lack robust clinical trials. The article calls for larger, randomized studies to validate these tools before they see wider adoption for health interventions. It’s a call to action for the longevity industry.
The architecture take
So, those biological age numbers you're tracking? They might not be telling the whole story yet. Nature Medicine just put a spotlight on epigenetic aging clocks, basically saying the science needs to catch up to the hype. We've been sold on the idea that these clocks can tell you if your lifestyle changes are actually working on a cellular level, but the trials just aren't there. I've always been wary of any biomarker that gets rolled out before its predictive power is truly solid. The paper isn't saying they're useless, just that we need proper, large-scale randomized studies to confirm they can really guide interventions. This changes how I look at some of the current longevity protocols; it means trusting the felt state of the body and established markers like VO2 max or DEXA still reigns supreme. Until then, use the clocks as a cool data point, not gospel.